Scarica l'app Stockscreener
10.79
1.64%
-0.18
Pre-mercato:
10.79
Panoramica
Notizia
Cronologia dei prezzi
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$10.97
Aprire:
$10.97
Volume 24 ore:
74,858
Relative Volume:
0.56
Capitalizzazione di mercato:
$328.52M
Reddito:
$6.67M
Utile/perdita netta:
$-47.55M
Rapporto P/E:
-7.1933
EPS:
-1.5
Flusso di cassa netto:
$-17.44M
1 W Prestazione:
-2.62%
1M Prestazione:
-22.76%
6M Prestazione:
-27.05%
1 anno Prestazione:
+2,010%
Intervallo 1D:
$10.55
$11.22
Intervallo di 1 settimana:
$10.55
$11.68
Portata 52W:
$9.81
$21.40
Crescent Biopharma Inc Stock (CBIO) Company Profile
Nome
Crescent Biopharma Inc
Settore
Industria
Telefono
617-430-5595
Indirizzo
300 FIFTH AVENUE, WALTHAM, CA
Confronta CBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
10.79 | 334.00M | 6.67M | -47.55M | -17.44M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-25 | Iniziato | Jefferies | Buy |
| 2025-08-11 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-14 | Iniziato | Wedbush | Outperform |
| 2025-06-25 | Iniziato | Stifel | Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-11 | Iniziato | Noble Capital Markets | Outperform |
| 2024-07-26 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-22 | Iniziato | CapitalOne | Overweight |
| 2021-11-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-04-29 | Ripresa | Stephens | Overweight |
| 2021-02-10 | Iniziato | Piper Sandler | Overweight |
| 2020-05-21 | Iniziato | Raymond James | Outperform |
| 2019-11-14 | Iniziato | ROTH Capital | Buy |
| 2019-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-05 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-04 | Iniziato | Oppenheimer | Outperform |
| 2018-12-18 | Iniziato | H.C. Wainwright | Buy |
| 2018-02-12 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Reiterato | Chardan Capital Markets | Buy |
| 2017-12-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Iniziato | Chardan Capital Markets | Buy |
| 2017-06-06 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-07-26 | Iniziato | SunTrust | Buy |
| 2016-06-30 | Iniziato | Rodman & Renshaw | Buy |
| 2015-03-17 | Reiterato | Stifel | Buy |
Mostra tutto
Crescent Biopharma Inc Borsa (CBIO) Ultime notizie
The deal that sent Crescent Biopharma shares surging over 40% pre-market today - MSN
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Crescent and Kelun announce IND approvals for CR-001, CR-003 - BioWorld MedTech
Crescent Biopharma Secures IND Clearances For Two Novel Oncology Candidates - Nasdaq
Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA - BioSpace
FDA clears Crescent’s CR-001 IND for solid tumor treatment By Investing.com - Investing.com South Africa
FDA clears Crescent’s CR-001 IND for solid tumor treatment - Investing.com
Two experimental cancer drugs cleared to begin human trials in U.S., China - Stock Titan
Crescent Biopharma, Inc. (CBIO) - MSN
Crescent Biopharma (CBIO) Stock Analysis Report | Financials & Insights - Benzinga
Crescent Biopharma price target raised to $32 from $28 at Stifel - MSN
Crescent Biopharma (NASDAQ:CBIO) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Crescent Biopharma (NASDAQ:CBIO) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Stifel Initiates Coverage of Crescent Biopharma (CBIO) with Buy Recommendation - MSN
Crescent Biopharma Announces Grants of Inducement Awards - The Manila Times
Can Crescent Biopharma Inc. (GKO0) stock sustain free cash flowWeekly Stock Recap & Trade Opportunity Analysis - Улправда
Is Crescent Biopharma Inc. (GKO0) stock dividend growth reliable2025 Growth vs Value & Safe Entry Trade Signal Reports - Улправда
Crescent Biopharma (CBIO) insider reports RSU and option awards - Stock Titan
Brokerages Set Crescent Biopharma, Inc. (NASDAQ:CBIO) Target Price at $26.40 - Defense World
Huge insider buying in MGM and Salesforce - MSN
Frazier Life Sciences Management L.P. Takes Position in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
CBIO Insider Trading - Quiver Quantitative
GlycoMimetics executives to depart amid merger plans - MSN
BVF Inc. IL Makes New Investment in Crescent Biopharma, Inc. $CBIO - MarketBeat
Braidwell LP Invests $4.22 Million in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma, Inc. (CBIO) Stock News & Articles - 24/7 Wall St.
Huge Insider Buying in MGM and Salesforce - 24/7 Wall St.
Crescent Biopharma (NASDAQ:CBIO) Director Fairmount Funds Management Llc Purchases 1,360,000 Shares of Stock - Defense World
Crescent, Kelun in two-way deal, including PD-1/VEGF bispecific - BioWorld MedTech
Fairmount Funds Management Llc Purchases 1,360,000 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock - MarketBeat
Shareholder Fairmount Funds Management LLC Buys 1,360,000 ($18.2M) Of Crescent Biopharma Inc [CBIO] - TradingView — Track All Markets
Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership - Indian Pharma Post
Sichuan Kelun-Biotech partners with Crescent Biopharma for oncology advancements - MSN
Affinity Asset Advisors LLC Makes New $4.52 Million Investment in Crescent Biopharma, Inc. $CBIO - MarketBeat
China's Kelun-Biotech licenses cancer treatment to Crescent Biopharma - Reuters
Crescent Biopharma (NASDAQ:CBIO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Lowered to “Sell” Rating by Wall Street Zen - Defense World
Crescent Biopharma partners with Kelun-Biotech in oncology - BioWorld MedTech
Crescent and Kelun-Biotech swap cancer asset rights in double deal - Yahoo Finance
Check Out Crescent Biopharma Inc (CBIO)’s Trade Data Rather Than the Analysts’ Views - setenews.com
Asia Deal Watch: Kelun And Crescent Partner And Cross-License Cancer Candidates - Citeline News & Insights
China’s Kelun-Biotech licenses cancer treatment to Crescent Biopharma - 1470 & 100.3 WMBD
Crescent Biopharma stock price target raised by Stifel to $32 on Kelun deal - Investing.com South Africa
Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Raises Target Price to $32 - 富途牛牛
Sichuan Kelun-Biotech biopharmaceutical partners with Crescent Biopharma - marketscreener.com
What's Happening With Crescent Biopharma Stock Today? - Benzinga
Crescent and Kelun-Biotech get creative with two-way licensing deal - The Pharma Letter
The Deal That Sent Crescent Biopharma Shares Surging Over 40% Pre-Market Today - Asianet Newsable
Why Is Crescent Biopharma Stock (CBIO) Up Today? - TipRanks
Kelun-Biotech and Crescent Biopharma announce strategic partnership - marketscreener.com
Crescent Biopharma Inc Azioni (CBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):